Story perspectives

Combination Therapies Boost Survival in Advanced Lung Cancer

9/8/2025

Summary

Story summary

The FLAURA2 trial showed that osimertinib combined with chemotherapy improves overall survival in EGFR-mutated advanced NSCLC, with a median OS of 47.5 months versus 37.6 months for osimertinib alone.
The ACROSS 2 trial found that aumolertinib with platinum-pemetrexed chemotherapy enhances progression-free survival, achieving a median PFS of 19.78 months compared to 16.53 months for monotherapy.
Both trials highlight the role of combination therapies in overcoming resistance and improving outcomes in advanced lung cancer.
Safety profiles for both combinations were manageable, with no new adverse events reported.
These results may shape future treatment guidelines and encourage research into personalized oncology strategies.

1 of 1

Story summary

The FLAURA2 trial showed that osimertinib combined with chemotherapy improves overall survival in EGFR-mutated advanced NSCLC, with a median OS of 47.5 months versus 37.6 months for osimertinib alone.
The ACROSS 2 trial found that aumolertinib with platinum-pemetrexed chemotherapy enhances progression-free survival, achieving a median PFS of 19.78 months compared to 16.53 months for monotherapy.
Both trials highlight the role of combination therapies in overcoming resistance and improving outcomes in advanced lung cancer.
Safety profiles for both combinations were manageable, with no new adverse events reported.
These results may shape future treatment guidelines and encourage research into personalized oncology strategies.